Biolinq

Thanks Nasdaq for celebrating our recent $58M funding, as we advance our wearable biosensors for #metabolic health. 🚀🚀 Press release: 👉 https://lnkd.in/etnifyNB WSJ: 👉 https://lnkd.in/eCWamfgr Drug Delivery Business: 👉 https://lnkd.in/gt2gpYsc Medical Device Network: 👉 https://lnkd.in/eUg9j-_X Longevity Technology: 👉 https://lnkd.in/e_AUEke5 MassDevice: 👉 https://lnkd.in/gt2gpYsc

We’re excited to share that our CEO Rich Yang and Olympic athlete Sky Christopherson will be on stage next week at the Fortune Brainstorm Tech Conference 2024! 🔥🔥🔥 Once again (now for 23 years), Fortune Brainstorm Tech brings together a community of Fortune 500 leaders with top investors, VCs, banking executives, startup founders, and global influencers. Sharing the list of speakers this year: https://lnkd.in/egWYBJAp More info about event: 👇👇 https://lnkd.in/e9nce9p9

Excited to announce that our CEO Rich Yang will be speaking at Fortune Brainstorm Tech next month! We will share more details closer to the event, July 15-17 in Park City, Utah. Once again (now for 23 years), Fortune Brainstorm Tech brings together a community of Fortune 500 leaders with top investors, VCs, banking executives, startup founders, and global influencers. The 2024 program will include insight and perspectives from a wide range of voices across the tech ecosystem. Learn more here: 👇👇 https://lnkd.in/e9nce9p9

Thanks IEEE Spectrum for speaking with our CEO Rich Yang about our intradermal sensors. Medical technology company Biolinq is developing a new type of glucose sensor that doesn’t go deeper than the dermis, the middle layer of skin that sits above the subcutaneous tissue. The company’s “intradermal” biosensors take advantage of metabolic activity in shallower layers of skin, using an array of electrochemical microsensors to measure glucose—and other chemicals in the body—just beneath the skin’s surface. Read the article: 👇👇👇 https://lnkd.in/evMWz9dH

Honored to have our CEO Rich Yang recognized as a finalist in the EY Entrepreneur Of The Year® 2024 Pacific Southwest program. We cannot wait to cheer him on during the awards celebration on June 7 when winners will be announced! #EOYUS #EOYPACSW Meet all the finalists: https://lnkd.in/ez8YCksS More info: https://lnkd.in/gD6sJPBS

Biolinq added $58M in a new funding round for its minimally-invasive glucose monitor. The company will complete clinical trials and seek FDA clearance this year. Challenging Dexcom and Abbott’s CGM hardware duopoly, Biolinq and other startups are racing to replace invasive sensors with needle-free alternatives. Meanwhile, tech giants Apple and Samsung are also investing heavily in metabolic health moonshots. Pending a tech breakthrough, blood sugar could become a major health metric for everyone — not just diabetics.

Thanks Katie Adams at MedCity News for speaking with our CEO Rich Yang about our recent funding and how our #glucose #biosensor is unique. “The reason that the papillary dermis is the best place on your body to sense biomarkers is because it is the single most metabolically active tissue you can be in that does not cause bleeding and does not cause pain. And it sits right on the top of the capillary bed — there’s no scarring in this zone of the tissue,” Yang explained. The biosensor world has been trying to access this part of the skin for decades, but conducting this type of research has been expensive and laborious, he noted. In order to access this part of your skin, “you have to be 200 times smaller than a human hair filament, yet be robust enough so that it doesn’t break,” he declared. Read the article: 👇👇 https://lnkd.in/gr9E5JAP

Good news, San Diego: 🤝 BAE Systems wins $182M contract from National Geospatial-Intelligence Agency 💰 Avenzo Therapeutics completes $150M Series A 🔬 Biolinq scores $58M to advance wearable biosensors More in #GNOTW, sponsored by Manpower San Diego ⤵️ https://lnkd.in/gazX7dxM

Bioworld with the catchy headline: 👀👀 Biolinq: Less pain, $58M gain for tiny glucose sensor In a sweet indication of an improving capital market for med-tech companies, Biolinq Inc. landed $58 million in bridge financing to support completion of the U.S. pivotal trial of its intradermal glucose sensor and submission to the U.S. FDA. The round brings the total raised to more than $170 million. With good response so far, the company is optimistic that it can attract more funding in short order. Read the article: https://lnkd.in/eru7BDTh

Thanks HIT Consultant Media for the thoughtful recap: https://lnkd.in/ewheXAzQ